- Home
- AEMD vs VIVS Comparison
AEMD vs VIVS Comparison
Compare AEMD & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEMD
- VIVS
- Stock Information
- Founded
- AEMD 1984
- VIVS 2007
- Country
- AEMD United States
- VIVS United States
- Employees
- AEMD N/A
- VIVS N/A
- Industry
- AEMD Medical/Dental Instruments
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AEMD Health Care
- VIVS Health Care
- Exchange
- AEMD Nasdaq
- VIVS Nasdaq
- Market Cap
- AEMD 4.1M
- VIVS 4.2M
- IPO Year
- AEMD N/A
- VIVS N/A
- Fundamental
- Price
- AEMD $1.22
- VIVS $1.45
- Analyst Decision
- AEMD Strong Buy
- VIVS
- Analyst Count
- AEMD 1
- VIVS 0
- Target Price
- AEMD $56.00
- VIVS N/A
- AVG Volume (30 Days)
- AEMD 265.2K
- VIVS 64.3K
- Earning Date
- AEMD 06-26-2025
- VIVS 07-07-2025
- Dividend Yield
- AEMD N/A
- VIVS N/A
- EPS Growth
- AEMD N/A
- VIVS N/A
- EPS
- AEMD N/A
- VIVS N/A
- Revenue
- AEMD N/A
- VIVS $144,000.00
- Revenue This Year
- AEMD N/A
- VIVS $42.38
- Revenue Next Year
- AEMD N/A
- VIVS $15.42
- P/E Ratio
- AEMD N/A
- VIVS N/A
- Revenue Growth
- AEMD N/A
- VIVS 32.11
- 52 Week Low
- AEMD $1.20
- VIVS $1.41
- 52 Week High
- AEMD $8.44
- VIVS $21.96
- Technical
- Relative Strength Index (RSI)
- AEMD 41.34
- VIVS N/A
- Support Level
- AEMD $1.40
- VIVS N/A
- Resistance Level
- AEMD $2.88
- VIVS N/A
- Average True Range (ATR)
- AEMD 0.26
- VIVS 0.00
- MACD
- AEMD -0.02
- VIVS 0.00
- Stochastic Oscillator
- AEMD 36.49
- VIVS 0.00
About AEMD Aethlon Medical Inc.
Aethlon Medical Inc is a medical therapeutic company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.